Healthcare

The healthcare company says it expects to post a narrower per-share loss in 2025.

The biopharma company is counting on KT-621 to treat patients with Type 2 inflammatory diseases.

Artificial intelligence is propping up the stock market, but healthcare is propping up the economy. Government actions might put that at risk, Ali R. Bustamante writes in a guest commentary.

A powerful federal public-health committee voted Friday to reverse decades-old vaccine guidance from the CDC.

The Trump administration is refocusing on RFK Jr.’s vaccine priorities. The CDC vaccine committee will vote again on hepatitis B guidelines.

It's the second time in a month that the psychiatric hospital operator has cut its earnings guidance.

The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.

Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Investors will be weighing up how to shield their portfolios in case the rebound loses steam. These stocks look tempting.

Walmart and TJX rallies indicate that U.S. consumers have plenty of fire power. Plus, investment newsletter commentary on healthcare stocks’ breakout, India’s attractions, and alternatives to the AI trade.

This phenomenon is far from dead. And it isn’t just Nvidia vs. Alphabet. Here’s a look behind the curtain.

Activists also report to the SEC on Acadia Healthcare, Butterly Network, National Energy Services Reunited, and Invivyd.

Google’s artificial-intelligence wins are bad news for Nvidia investors, Trump and Xi make plans amid rising Taiwan tensions, more news to start your day.

Alphabet stock continues its surge on the back of excitement around Google’s latest large-language model, while Tesla rises after CEO Elon Musk indicates the electric-vehicle maker has designed AI chips for its cars and data centers.

The White House is planning to propose a two-year extension for Affordable Care Act subsidies, according to a report.

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.

Premiums for “Obamacare” plans will spike next year if Congress doesn’t act. Health Savings Accounts could be a fix.

The maker of an implant to treat sleep apnea receives an upgrade to Buy from Hold at Stifel.

Morgan Stanley is bullish on the S&P 500 over the next year, and likes discretionary goods, healthcare, financials, industrials, and small-caps too.

It’s the only drug company ever to have a $1 trillion capitalization value; the other U.S. companies are tech giants and Berkshire Hathaway.

Thursday, GE Healthcare announced an agreement to acquire Intelerad, a medical imaging software provider for $2.3 billion in cash.

Healthcare stocks may have more momentum. But the AI trade isn’t dead yet.

Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.